MVZ Leipzig Mitte
- Address
- Johannisplatz 1, Zentrum-Südost, 04103 Leipzig, Germany
MVZ Leipzig Mitte - Oncology and Hematology Research Center
MVZ Leipzig Mitte is a specialized medical research facility focusing on advanced clinical trials in oncology and hematologic malignancies. The center demonstrates particular expertise in evaluating novel therapeutic combinations for complex blood disorders and gastrointestinal cancers, contributing to the development of innovative treatment strategies for patients with challenging diagnoses.
- Myeloproliferative neoplasms including primary myelofibrosis with targeted combination therapies
- Gastroesophageal adenocarcinomas utilizing perioperative immunotherapy approaches
- Advanced clinical trial methodology including Phase II/III efficacy and safety studies
The center's research portfolio includes investigating combination therapies such as navtemadlin with ruxolitinib for myelofibrosis patients, focusing on symptom reduction and spleen volume improvements. Additionally, MVZ Leipzig Mitte participates in international collaborative studies examining immunotherapy combinations with chemotherapy regimens for locally advanced gastric and esophagogastric junction adenocarcinomas, emphasizing patient selection based on immune responsiveness profiles.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Kartos Therapeutics Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MVZ Leipzig Mitte
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multi-center, open-label, single-arm study to evaluate the efficacy and safety of oral rilzabrutinib in adults with immune thrombocytopenia (ITP) who failed first-line treatment | Sanofi-Aventis Recherche & Developpement | Phase III | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atezolizumab | 1 | Unknown | 2018-09-03 | 2018-09-03 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.